

Mara Reig

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5129924/maria-reig-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

113
papers

10,264
citations

36
h-index

101
g-index

139
ext. papers

13,163
ext. citations

6
avg, IF

6.97
L-index

#	Paper	IF	Citations
113	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018 , 391, 1301-1314	40	2402
112	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016 , 150, 835-53	13.3	1012
111	Current strategy for staging and treatment: the BCLC update and future prospects. <i>Seminars in Liver Disease</i> , 2010 , 30, 61-74	7.3	770
110	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016 , 65, 719-726	13.4	709
109	Management of HCC. <i>Journal of Hepatology</i> , 2012 , 56 Suppl 1, S75-87	13.4	438
108	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016 , 64, 1090-1098	13.4	407
107	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. <i>Cancer</i> , 2009 , 115, 616-23	6.4	359
106	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012 , 56, 1330-5	13.4	354
105	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology, The</i> , 2018 , 19, 682-693	21.7	216
104	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010 , 51, 2020-9	11.2	209
103	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. <i>Hepatology</i> , 2015 , 61, 526-36	11.2	207
102	Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009 , 50, 791-8	11.2	207
101	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. <i>Annual Review of Medicine</i> , 2010 , 61, 317-28	17.4	189
100	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013 , 49, 3412-9	7.5	178
99	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014 , 61, 318-24	13.4	172
98	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. <i>Hepatology</i> , 2013 , 58, 2023-31	11.2	162
97	Non-invasive diagnosis of hepatocellular carcinoma \geq 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012 , 56, 1317-23	13.4	135

96	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <i>Journal of Hepatology</i> , 2021 ,	13.4	127
95	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. <i>Gut</i> , 2012 , 61, 1481-7	19.2	121
94	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012 , 56, 103-8	13.4	114
93	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015 , 275, 698-707	20.5	99
92	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018 , 68, 16-24	14.4	89
91	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. <i>Hepatology</i> , 2011 , 54, 2238-44	11.2	84
90	Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. <i>Seminars in Liver Disease</i> , 2014 , 34, 444-55	7.3	83
89	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 617-630	24.2	82
88	Evoluci3 natural y estratificaci3 del carcinoma hepatocelular. <i>Clinical Liver Disease</i> , 2013 , 2, S33-S36	2.2	78
87	Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. <i>Gastroenterology</i> , 2009 , 137, 26-9	13.3	77
86	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020 , 72, 320-341	13.4	68
85	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 327-327	2.2	64
84	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017 , 37, 109-118	7.3	59
83	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016 , 34, 597-602	3.2	51
82	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019 , 70, 874-884	13.4	44
81	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018 , 67, 612-622	11.2	44
80	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019 , 19, 3176-3184	8.7	43
79	New trials and results in systemic treatment of HCC. <i>Journal of Hepatology</i> , 2018 , 69, 525-533	13.4	39

78	Should Patients With NAFLD/NASH Be Surveyed for HCC?. <i>Transplantation</i> , 2019 , 103, 39-44	1.8	33
77	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2018 , 9, 16701-16717	3.3	32
76	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 482-491	6.1	30
75	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 328-349	0.9	30
74	Treatment of hepatocellular carcinoma. <i>Digestive Diseases</i> , 2014 , 32, 554-63	3.2	29
73	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules. <i>Journal of Hepatology</i> , 2015 , 62, 150-5	13.4	28
72	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010 , 42 Suppl 3, S242-8	3.3	27
71	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019 , 1, 17-29	10.3	26
70	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4000-4000	2.3	26
69	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37 Suppl 1, 136-139	7.9	25
68	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021 , 75, 600-609	13.4	25
67	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	21
66	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009 , 29 Suppl 1, 148-58	7.9	19
65	New Systemic Treatments in Advanced Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2019 , 25, 311-325	2.5	17
64	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020 , 24, 719-737	4.6	14
63	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021 , 74, 1225-1233	1.3	14
62	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica</i> , 2017 , 149, 61-71	1	13
61	The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021 , 13,	6.6	13

60	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1923-36	4	12
59	HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.. <i>Journal of Hepatology</i> , 2022 ,	13.4	11
58	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
57	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260.3	0.3	11
56	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020 , 30, 186-194	8	11
55	Lenvatinib: can a non-inferiority trial change clinical practice?. <i>Lancet, The</i> , 2018 , 391, 1123-1124	40	10
54	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020 , 31, 710-719	2.4	10
53	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , 2020 , 12,	6.6	9
52	Systemic treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 921-35	2.5	9
51	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017 , 23, 2448-2452	5.6	9
50	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021 , 135, 109484	4.7	9
49	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020 , 40, 1467-1476	7.9	8
48	Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. <i>Annals of Surgery</i> , 2015 , 261, e105	7.8	8
47	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1041-1046	3.3	7
46	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016 , 65, 864-865	13.4	6
45	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 502-511	0.9	6
44	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020 , 12,	6.6	6
43	Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. <i>Viruses</i> , 2019 , 11,	6.2	5

42	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012 , 1, 183-185	2.2	4
41	Sorafenib for hepatocellular carcinoma: global validation. <i>Gastroenterology</i> , 2009 , 137, 1171-3	13.3	4
40	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , 2022 , 11, 75-84	9.1	4
39	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021 , 41, 598-607	7.9	4
38	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 751-2	21.7	3
37	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020 , 30, 6694-6701	8	3
36	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , 2014 , 61, 164-5	13.4	3
35	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 13,	6.6	3
34	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021 , 75, 1154-1163	13.4	3
33	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules \geq cm in cirrhotic patients. <i>European Radiology</i> , 2021 , 31, 4794-4803	8	3
32	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021 , 27, 1767-1778	4.5	3
31	Current pharmacological treatment of hepatocellular carcinoma. <i>Current Opinion in Pharmacology</i> , 2021 , 60, 141-148	5.1	3
30	SAT-482-Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program. <i>Journal of Hepatology</i> , 2019 , 70, e845	13.4	2
29	Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 1197-9	2.4	2
28	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 263-270	3	2
27	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , 2021 , 156, 463.e1-463.e30	1	2
26	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021 , 12, 555	9.8	2
25	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2

24	Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. <i>Antioxidants</i> , 2021 , 10,	7.1	2
23	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. <i>European Journal of Medical Genetics</i> , 2021 , 64, 104313	2.6	2
22	Systemic Treatment: Expecting Further Success. <i>Digestive Diseases</i> , 2015 , 33, 590-7	3.2	1
21	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica (English Edition)</i> , 2017 , 149, 61-71	0.3	1
20	The search for an effective partner for sorafenib: the failure of doxorubicin. <i>Gastroenterology</i> , 2011 , 140, 1687-8	13.3	1
19	Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010 , 17, 420-1	2.8	1
18	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
17	Reply to: "The reported clear cut time association between interferon-free treatment and HCCRs anything but clear cut". <i>Journal of Hepatology</i> , 2020 , 72, 1036-1037	13.4	1
16	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020 , 40, 2476-2488	7.9	1
15	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021 , 9, 655-661	5.3	1
14	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016 , 146, 511.e1-511.e22	0.3	1
13	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 328-349	0.1	1
12	Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study.. <i>Lancet Oncology, The</i> , 2022 , 23, 4-6	21.7	0
11	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 428-428	2.2	0
10	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021 , 12, 440-449	3.3	0
9	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 463.e1-463.e30	0.3	0
8	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". <i>Journal of Hepatology</i> , 2019 , 71, 447-448	12.4	1
7	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 502-511	0.1	1

6	Reply: To PMID 25212123. <i>Hepatology</i> , 2015 , 62, 978-9	11.2
5	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterology & Hepatology</i> , 2022 ,	0.9
4	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 , 117-131	0.3
3	Tumors of the Liver773-785	
2	Letter: are sorafenib-related adverse events associated with prolonged survival? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 192	6.1
1	Reply to: "Correspondence on the ". <i>Journal of Hepatology</i> , 2022 ,	13.4